2 completed. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 2 |
| Phase 2 | 1 | Completed 1 |
Follow Clesrovimab: new trials by email Literature Review of Clesrovimab trials Research Report on Clesrovimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007) Clesrovimab, Palivizumab, Placebo - RSV Infection | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1003 | 2021-11-30 | 2026-05-08 |
| Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004) Clesrovimab, Placebo - Respiratory Syncytial Virus Infection | Phase 2 / Phase 3 | Completed | Merck Sharp & Dohme LLC | 3632 | 2021-04-07 | 2026-02-11 |
Respiratory Syncytial Virus Infections (2)
Canada (2) · Chile (2) · Colombia (2) · Finland (2) · France (2) · Italy (2) · Japan (2) · Malaysia (2) · Mexico (2) · Peru (2) · South Africa (2) · Thailand (2) · Turkey (Türkiye) (2) · United Kingdom (2) · United States (2)
PMID 34774184, PMID 40602662, PMID 40673795, PMID 40961423, PMID 40961446, PMID 42475081